These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 22230573

  • 1. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
    Pardridge WM, Boado RJ.
    Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
    [Abstract] [Full Text] [Related]

  • 2. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.
    Zhou QH, Boado RJ, Pardridge WM.
    J Drug Target; 2012 Sep; 20(8):715-9. PubMed ID: 22845843
    [Abstract] [Full Text] [Related]

  • 3. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier.
    Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM.
    Biotechnol Bioeng; 2008 Feb 01; 99(2):475-84. PubMed ID: 17680664
    [Abstract] [Full Text] [Related]

  • 4. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier.
    Boado RJ, Zhang Y, Zhang Y, Pardridge WM.
    Biotechnol Bioeng; 2007 Aug 15; 97(6):1376-86. PubMed ID: 17286273
    [Abstract] [Full Text] [Related]

  • 5. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses.
    Pardridge WM.
    Bioconjug Chem; 2008 Jul 15; 19(7):1327-38. PubMed ID: 18547095
    [Abstract] [Full Text] [Related]

  • 6. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
    Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM.
    Mol Pharm; 2010 Dec 06; 7(6):2148-55. PubMed ID: 20860349
    [Abstract] [Full Text] [Related]

  • 7. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse.
    Boado RJ, Hui EK, Lu JZ, Pardridge WM.
    J Pharmacol Exp Ther; 2010 Jun 06; 333(3):961-9. PubMed ID: 20233799
    [Abstract] [Full Text] [Related]

  • 8. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.
    Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM.
    J Biotechnol; 2010 Mar 06; 146(1-2):84-91. PubMed ID: 20100527
    [Abstract] [Full Text] [Related]

  • 9. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.
    Lu JZ, Hui EK, Boado RJ, Pardridge WM.
    Bioconjug Chem; 2010 Jan 06; 21(1):151-6. PubMed ID: 20000684
    [Abstract] [Full Text] [Related]

  • 10. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier.
    Boado RJ, Zhang Y, Zhang Y, Pardridge WM.
    Biotechnol Bioeng; 2007 Feb 01; 96(2):381-91. PubMed ID: 16937408
    [Abstract] [Full Text] [Related]

  • 11. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery.
    Boado RJ.
    Drug News Perspect; 2008 Nov 01; 21(9):489-503. PubMed ID: 19180267
    [Abstract] [Full Text] [Related]

  • 12. Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.
    Pardridge WM.
    BioDrugs; 2017 Dec 01; 31(6):503-519. PubMed ID: 29067674
    [Abstract] [Full Text] [Related]

  • 13. Biopharmaceutical drug targeting to the brain.
    Pardridge WM.
    J Drug Target; 2010 Apr 01; 18(3):157-67. PubMed ID: 20064077
    [Abstract] [Full Text] [Related]

  • 14. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey.
    Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM.
    Bioconjug Chem; 2013 Oct 16; 24(10):1741-9. PubMed ID: 24059813
    [Abstract] [Full Text] [Related]

  • 15. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
    Pardridge WM.
    Expert Opin Drug Deliv; 2015 Feb 16; 12(2):207-22. PubMed ID: 25138991
    [Abstract] [Full Text] [Related]

  • 16. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.
    Hui EK, Boado RJ, Pardridge WM.
    Mol Pharm; 2009 Feb 16; 6(5):1536-43. PubMed ID: 19624167
    [Abstract] [Full Text] [Related]

  • 17. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse.
    Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM.
    Drug Metab Dispos; 2012 Feb 16; 40(2):329-35. PubMed ID: 22065691
    [Abstract] [Full Text] [Related]

  • 18. IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier.
    Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM.
    Mol Pharm; 2008 Feb 16; 5(6):1037-43. PubMed ID: 19434854
    [Abstract] [Full Text] [Related]

  • 19. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
    Boado RJ, Zhang Y, Wang Y, Pardridge WM.
    Biotechnol Bioeng; 2009 Mar 01; 102(4):1251-8. PubMed ID: 18942151
    [Abstract] [Full Text] [Related]

  • 20. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
    Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM.
    Mol Pharm; 2011 Aug 01; 8(4):1342-50. PubMed ID: 21667973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.